These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 38164722)
1. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors. Basu D; Pal R; Sarkar M; Barma S; Halder S; Roy H; Nandi S; Samadder A Curr Top Med Chem; 2023; 23(30):2877-2972. PubMed ID: 38164722 [TBL] [Abstract][Full Text] [Related]
2. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. Sie M; den Dunnen WF; Lourens HJ; Meeuwsen-de Boer TG; Scherpen FJ; Zomerman WW; Kampen KR; Hoving EW; de Bont ES PLoS One; 2015; 10(3):e0122555. PubMed ID: 25799134 [TBL] [Abstract][Full Text] [Related]
3. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents. Nandi S; Dey R; Samadder A; Saxena A; Saxena AK Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823 [TBL] [Abstract][Full Text] [Related]
4. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Jiao Y; Ou W; Meng F; Zhou H; Wang A Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship. Taruneshwar Jha K; Shome A; Chahat ; Chawla PA Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103 [TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases and targeted cancer therapeutics. Takeuchi K; Ito F Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229 [TBL] [Abstract][Full Text] [Related]
7. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463 [TBL] [Abstract][Full Text] [Related]
8. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422 [TBL] [Abstract][Full Text] [Related]
9. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy. Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660 [TBL] [Abstract][Full Text] [Related]
16. The JAK/STAT signaling cascade in gastric carcinoma (Review). Khanna P; Chua PJ; Bay BH; Baeg GH Int J Oncol; 2015 Nov; 47(5):1617-26. PubMed ID: 26398764 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Patwardhan PP; Musi E; Schwartz GK Mol Cancer Ther; 2018 Nov; 17(11):2329-2340. PubMed ID: 30166401 [TBL] [Abstract][Full Text] [Related]
18. RTK Inhibitors in Melanoma: From Bench to Bedside. Sabbah M; Najem A; Krayem M; Awada A; Journe F; Ghanem GE Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918490 [TBL] [Abstract][Full Text] [Related]
19. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198 [TBL] [Abstract][Full Text] [Related]
20. Phylogenetic and transcriptomic characterization of insulin and growth factor receptor tyrosine kinases in crustaceans. Flores KA; Pérez-Moreno JL; Durica DS; Mykles DL Front Endocrinol (Lausanne); 2024; 15():1379231. PubMed ID: 38638139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]